Current drug therapies: relievers and preventers

Area of Science:

• Pediatric Pulmonology
• Asthma Phenotyping
• Clinical Therapeutics

Background:

• Childhood wheezing presents diverse phenotypes impacting treatment response.
• Beta-agonists are effective for acute asthma; anticholinergics offer added benefit from 18 months.
• Non-steroidal and inhaled corticosteroid therapies show variable efficacy depending on asthma severity and phenotype.

Purpose of the Study:

• To explore the potential for distinguishing early childhood wheezing phenotypes at presentation.
• To determine the relative benefits of reliever and preventer medications for different wheezing phenotypes.
• To investigate the long-term impact of early asthma treatment on disease development and lung function.

Main Methods:

• Utilizing clinical features and markers of airway inflammation/hyperresponsiveness to differentiate phenotypes.
• Evaluating the efficacy and dose-response of inhaled corticosteroids in infants and young children.
• Assessing potential side effects, including growth suppression, from inhaled corticosteroid use.

Main Results:

• Current knowledge suggests inhaled corticosteroids are effective for persistent asthma but not episodic viral wheeze.
• Evidence is lacking on the long-term effects of inhaled corticosteroids on childhood asthma outcomes.
• The efficacy of different treatment strategies across various wheezing phenotypes remains under investigation.

Conclusions:

• Distinguishing wheezing phenotypes is essential for targeted pediatric asthma therapy.
• Further research is needed to optimize reliever and preventer medication use in early childhood asthma.
• The long-term benefits and risks of early inhaled corticosteroid treatment require further elucidation.